Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

How were the studies completed that looked at the systemic absorption of topical ruxolitinib cream and what can clinicians glean from this information?

Atopic Dermatitis

You in evaluating any topical therapy for any disease. In this case atopic dermatitis, we have concern about how much is systemically absorbed. In the case of topical ruxalitinib, the recommendation in the package insert is using it in patients twelve years of age and older for up to eight weeks, essentially not continuous, but only when the disease is there. When it's significantly better or cleared, you stop the drug and also less than 20% body surface area. There were maximum use studies where they included both patients twelve to 17 and 18 years of age and older where the mean area of application mean body surface area was 37.5% and it was more than 25%. Many patients applying more than 40% body surface area and we did not see any accumulation of the drug over the 28 days of twice daily application. In patients with mild, moderate or severe atopic dermatitis. Certainly you want to stay below that 20% body surface area and use it only where the disease is present and there's a very good safety cushion with regard to avoiding any significant adverse events. Thank.

How were the studies completed that looked at the systemic absorption of topical ruxolitinib cream and what can clinicians glean from this information?

Related CME